Page 105 - Read Online

Page 14 of 18 Alqahtani et al. Hepatoma Res 2020;6:58 I http://dx.doi.org/10.20517/2394-5079.2020.49

32. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological
gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
33. Wong VW, Sung JJ. Diagnosis and personalized management of hepatitis B including significance of genotypes. Curr Opin Infect Dis
2012;25:570-7.
34. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in
hepatitis B carriers. Gastroenterology 2003;124:327-34.
35. Wong GL, Chan HL, Yiu KK, Lai JW, Chan VK, et al. Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular
carcinoma. Aliment Pharmacol Ther 2013;37:517-26.
36. Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, et al. Prediction of development of liver-related events by transient elastography in hepatitis
B patients with complete virological response on antiviral therapy. Am J Gastroenterol 2014;109:1241-9.
37. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver
disease. Hepatology 2003;37:19-26.
38. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, et al. Statements from the Taormina expert meeting on occult hepatitis B
virus infection. J Hepatol 2008;49:652-7.
39. Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol 2014;20:5951-61.
40. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, et al; Taormina Workshop on Occult HBV Infection Faculty Members.
Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 2019;71:397-408.
41. Wang H, Swann R, Thomas E, Innes HA, Valerio H, et al. Impact of previous hepatitis B infection on the clinical outcomes from chronic
hepatitis C? A population-level analysis. J Viral Hepat 2018;25:930-8.
42. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related
hepatocellular carcinoma: a prospective study. Ann Intern Med 2007;146:649-56.
43. Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti-HBc positivity and hepatocellular carcinoma in
HBsAg-negative subjects with chronic liver disease: a meta-analysis. Medicine (Baltimore) 2016;95:e4311.
44. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, et al; Italian Association of the Study of the Liver Disease (AISF). Lack
of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. Am J
Gastroenterol 2008;103:1966-72.
45. Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, et al. Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular
carcinoma. Liver Int 2014;34:e144-50.
46. Kim JH, Kim MN, Han KH, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving
antiviral treatment. Liver Int 2015;35:1103-15.
47. Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development
using liver stiffness measurement (FibroScan). Hepatology 2011;53:885-94.
48. Huang R, Jiang N, Yang R, Geng X, Lin J, et al. Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic
hepatitis B. Exp Ther Med 2016;11:1673-7.
49. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, et al. Independent risk factors and predictive score for the development of
hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-8.
50. Wong GL, Chan HL, Wong CK, Leung C, Chan CY, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in
patients with chronic hepatitis B. J Hepatol 2014;60:339-45.
51. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in
Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800-6.
52. Jung KS, Kim SU, Song K, Park JY, Kim DY, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in
the era of antiviral therapy. Hepatology 2015;62:1757-66.
53. Sung WK, Zheng H, Li S, Chen R, Liu X, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat
Genet 2012;44:765-9.
54. Wang M, Xi D, Ning Q. Virus-induced hepatocellular carcinoma with special emphasis on HBV. Hepatol Int 2017;11:171-80.
55. Wu S, Kanda T, Nakamoto S, Jiang X, Nakamura M, et al. Cooperative effects of hepatitis B virus and TNF may play important roles in
the activation of metabolic pathways through the activation of NF-κB. Int J Mol Med 2016;38:475-81.
56. Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. In: Cai Q, Yuan Z, Lan K, editors. Infectious Agents Associated Cancers:
Epidemiology and Molecular Biology. Singapore: Springer; 2017. pp. 11-21.
57. Wang W, Bian H, Li F, Li X, Zhang D, et al. HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via
promoting production of inflammatory cytokines. Cell Mol Life Sci 2018;75:2627-41.
58. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, et al. Deregulation of microRNA expression occurs early and accumulates in early stages
of HBV-associated multistep hepatocarcinogenesis. J Hepatol 2011;54:1177-84.
59. Tian Y, Ou JH. Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma. Virol Sin 2015;30:85-91.
60. Kanda T, Wu S, Sasaki R, Nakamura M, Haga Y, et al. HBV core protein enhances cytokine production. Diseases 2015;3:213-20.
61. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature
1991;351:317-20.
62. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular
carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci 2019;20:1358.
63. WHO. Global health sector strategy on viral hepatitis 2016-2021. Geneva, Switzerland: WHO; 2016.